Heart failure with preserved ejection fraction management requires phenotype-specific therapeutic approaches, as traditional neurohormonal therapies have shown limited efficacy in improving mortality.
This review highlights the evolving diagnostic criteria, complex pathophysiology, and challenging management landscape of HFpEF, emphasizing the need for targeted therapies based on specific phenotypes.
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for nearly half of the cases of HF and its incidence might be increasing with the aging society. Patients with HFpEF present with significant symptoms, including exercise intolerance, impaired quality of life, and have a poor prognosis as well as frequent hospitalization and increased mortality compared with HF with reduced ejection fraction. The concept of HFpEF is still evolving and may be a virtual complex rather than a real systemic disorder. Thus, beyond solely targeting cardiac abnormalities management strategies need to be extended, such as left ventricular diastolic dysfunction. In this review, we examine new diagnostic algorithms, pathophysiology, current management status, and ongoing trials based on heterogeneous pathophysiology and etiology in HFpEF.
Kim et al. (Wed,) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Heart failure with preserved ejection fraction management requires phenotype-specific therapeutic approaches, as traditional neurohormonal therapies have shown limited efficacy in improving mortality.